Amgen
AMGN
$417.57
+0.65%
Amgen Inc. is a biotechnology leader focused on human therapeutics, with a flagship portfolio spanning red blood cell boosters (Epogen, Aranesp), immune system boosters (Neupogen, Neulasta), inflammatory disease drugs (Enbrel, Otezla), bone-strengthening agents (Prolia, Xgeva, Evenity), and a growing oncology and rare-disease franchise bolstered by the 2023 Horizon acquisition (Tepezza, Krystexxa, Uplizna). The company operates at scale in the general drug manufacturing industry, distinguishing itself as one of the largest independent biotechs with a diversified, multi-franchise model and an emerging biosimilar business. The current investor narrative centers on the potential of MariTide, Amgen's once-monthly obesity candidate, which could carve a niche in a market dominated by Eli Lilly and Novo Nordisk, while also weighing pipeline setbacks such as regulatory scrutiny around Tavneos and the overhang of proposed 100% drug tariffs that could reshape industry economics. Recent analyst actions have skewed cautious, with several firms trimming ratings to Hold or Neutral, reflecting a debate over whether Amgen's growth trajectory can offset competitive and policy pressures.…
AMGN
Amgen
$417.57
Related headlines
Investment Opinion: Should I buy AMGN Today?
We assign a Hold rating to Amgen. The core thesis is that Amgen's diversified revenue base, strong free cash flow, and attractive forward valuation are offset by a 'hold' analyst consensus, a target price below the current price, and significant pipeline and regulatory uncertainties. The average analyst target of $395.25 implies a 4.7% downside from the current price of $414.87, suggesting limited near-term upside. While the dividend yield of 2.9% and low PEG ratio of 0.26 are appealing, the risk/reward is balanced at current levels.
Supporting evidence for the Hold includes: 1) Revenue growth of 9.7% year-over-year in Q2 2026, driven by volume growth and new product launches; 2) Net margin of 21.0% and operating margin of 29.1%, which are solid but below the company's historical peaks; 3) Free cash flow of $10.2 billion, providing ample coverage for the dividend and reinvestment; 4) The forward P/E of 16.9x is below the trailing P/E of 22.8x, but the stock trades at a premium to the analyst average target. Compared to the drug manufacturing industry, Amgen's valuation is not egregiously high, but the high debt-to-equity ratio of 6.31 is a notable outlier.
The biggest risks that could invalidate the Hold rating are: 1) MariTide clinical or commercial failure, which would remove a key growth catalyst; 2) Adverse regulatory outcomes, such as the implementation of 100% drug tariffs or further Tavneos issues; 3) Deterioration in margins or cash flow due to competitive pressure. The rating would upgrade to Buy if the stock pulls back to the $350–370 range (providing a margin of safety) or if MariTide shows compelling Phase 3 data. It would downgrade to Sell if revenue growth decelerates below 5% or if free cash flow declines significantly. Relative to its history and peers, AMGN appears fairly valued to slightly overvalued at current levels.
Sign up to view all
AMGN 12-Month Price Forecast
Amgen presents a balanced risk/reward profile. The company's diversified revenue base, strong cash flow, and attractive forward valuation are offset by high leverage, regulatory uncertainties, and intense competition in the obesity market. The analyst consensus is 'hold' with a target price below the current price, suggesting limited near-term upside. However, the stock's relative strength and low PEG ratio indicate that the market may be underestimating its growth potential. We would upgrade to bullish if MariTide shows compelling Phase 3 data or if the stock pulls back to the $350–370 range. We would downgrade to bearish if revenue growth decelerates below 5% or if free cash flow deteriorates significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $395.25 and implied upside of -5.3% versus the current price.
Average Target
$395.25
0 analysts
Implied Upside
-5.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$225 - $500
Analyst target range
Bulls vs Bears: AMGN Investment Factors
The bull case rests on Amgen's diversified revenue base, strong cash flow, attractive forward valuation, and the optionality from MariTide in the obesity market. The bear case highlights the stock's premium valuation relative to analyst targets, high leverage, regulatory risks, and intense competition. Currently, the bear evidence appears slightly stronger: the consensus rating is 'hold' with a target price below the current price, and the debt burden is substantial. However, the bull case is supported by impressive relative strength and a low PEG ratio. The single most important tension is whether MariTide can achieve commercial success and drive meaningful revenue growth, offsetting competitive pressures and justifying the current valuation. If MariTide data disappoints or is delayed, the stock could face a significant de-rating.
Bullish
- MariTide obesity optionality: Amgen's once-monthly MariTide could carve a differentiated niche in the obesity market dominated by Eli Lilly and Novo Nordisk. With the obesity market potentially exceeding $100 billion, even a modest share could add billions in annual revenue, and the convenience of monthly dosing may drive superior adherence versus weekly injections.
- Strong relative performance vs. market: AMGN has outperformed the S&P 500 by 24.4 percentage points over the past year (40.4% vs. 16.0% for SPY) and by 12.5 percentage points year-to-date. This relative strength suggests the market is rewarding Amgen's pipeline and earnings execution despite a 'hold' consensus rating.
- Attractive forward valuation: The forward P/E of 16.9x is well below the trailing P/E of 22.8x, implying expected earnings growth. The PEG ratio of 0.26 is exceptionally low, suggesting the stock is undervalued relative to its growth prospects, especially compared to many large-cap biotech peers trading at 20x+ forward earnings.
- Robust cash generation and dividend: Amgen generated $10.2 billion in trailing free cash flow, comfortably covering its dividend (payout ratio 66.5%) and supporting reinvestment in R&D ($1.87 billion in Q2 alone). The 2.9% dividend yield is attractive for income-oriented investors in the biotech space.
Bearish
- Analyst consensus is only 'hold': Of 29 analysts covering AMGN, the average recommendation is 2.65 (hold), with an average target price of $395.25, which is 4.7% below the current price of $414.87. This suggests limited near-term upside according to the analyst community, and several firms have recently downgraded the stock to Hold or Neutral.
- High leverage and low current ratio: Amgen's debt-to-equity ratio of 6.31 is exceptionally high, reflecting the debt-funded Horizon acquisition. The current ratio of 1.14 is barely above 1, indicating limited short-term liquidity cushion. Interest expense of $673 million in Q2 alone consumes a significant portion of operating income.
- Regulatory and legal overhangs: The Tavneos controversy, with partner warnings about data manipulation and safety concerns, poses reputational and financial risk. Additionally, proposed 100% drug tariffs could disrupt industry economics, and Amgen's exposure depends on whether it secures a pricing deal exemption.
- Intense obesity competition: MariTide will face entrenched competition from Eli Lilly's Zepbound and Novo Nordisk's Wegovy, as well as emerging players like Pfizer's berobenatide. Amgen is a late entrant, and capturing meaningful market share will require superior efficacy, tolerability, and manufacturing scale.
AMGN Technical Analysis
Beta
0.41
0.41x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$288-$447
Price range past year
Annual Return
+43.9%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | +10.7% | +1.8% |
| 3m | +17.5% | +3.5% |
| 6m | +19.9% | +11.2% |
| 1y | +43.9% | +19.1% |
| ytd | +27.4% | +14.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Quarterly Revenue
$10.1B
2026-06
Revenue YoY Growth
+9.7%
YoY Comparison
Gross Margin
72.0%
Latest Quarter
Free Cash Flow
$10.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
PE
22.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 11x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Amgen's financial risk profile is dominated by its elevated debt load, with a debt-to-equity ratio of 6.31, a legacy of the $27.8 billion Horizon Therapeutics acquisition. Interest expense totaled $673 million in Q2 2026 alone, consuming roughly 19% of operating income. The current ratio of 1.14 provides a thin liquidity buffer, and while free cash flow of $10.2 billion comfortably covers the dividend (payout ratio 66.5%), any deterioration in cash flow could pressure the company's ability to deleverage or invest in pipeline growth. Additionally, earnings volatility is notable: quarterly EPS has ranged from $2.45 to $5.93 over the past five quarters, and gross margin fell to 72.0% in Q2 2026 from 81.9% in Q4 2025, reflecting rising costs and acquisition-related amortization.
Market and competitive risks are significant. Amgen trades at a forward P/E of 16.9x and a trailing P/E of 22.8x, which may appear reasonable, but the PEG ratio of 0.26 suggests the market is pricing in low growth expectations. The beta of 0.41 indicates low correlation with the broader market, but sector rotation away from healthcare could still pressure the stock. Competitive threats are intensifying: Eli Lilly and Novo Nordisk dominate the obesity market, and Pfizer's berobenatide could further crowd the space. Regulatory risks include the proposed 100% drug tariffs, which could disrupt global supply chains and pricing, and the Tavneos data manipulation scandal, which has led partners to urge caution and could result in fines or sales restrictions.
In a worst-case scenario, a combination of MariTide failure or delay, tariff implementation, and continued margin erosion could drive the stock down to its 52-week low of $288, representing a 30.6% decline from the current price of $414.87. The analyst low target of $225 implies an even steeper 45.8% downside, though that appears overly pessimistic. A more realistic bear case might see the stock retrace to the $300–320 range, a 23–28% drop, if growth stalls and the market re-rates the stock to a lower multiple. The maximum drawdown over the past 180 days was -16.6%, but a more severe scenario could exceed that given the high leverage and binary pipeline events.
FAQ
The key risks include: 1) Financial risk: high debt-to-equity of 6.31 and interest expense of $673 million per quarter, which could strain cash flow if earnings decline. 2) Competitive risk: intense competition in the obesity market from Eli Lilly and Novo Nordisk, and potential new entrants like Pfizer. 3) Regulatory risk: proposed 100% drug tariffs and the Tavneos data manipulation scandal could lead to fines, sales restrictions, or reputational damage. 4) Pipeline risk: MariTide may fail to differentiate or face delays, removing a key growth catalyst. These risks are ranked from high to moderate severity, with financial and competitive risks being the most immediate.
Our 12-month forecast for AMGN includes three scenarios: Bull case (25% probability) with a target range of $460–500, driven by successful MariTide data and tariff resolution; Base case (55% probability) with a target range of $380–420, assuming steady execution and moderate growth; Bear case (20% probability) with a target range of $288–320, triggered by pipeline failures or regulatory setbacks. The base case is most likely, with a midpoint around $400, implying a slight decline from the current price. The key assumption is that Amgen continues to grow revenue at 5-7% annually and maintains its dividend, while MariTide achieves modest commercial success.
AMGN appears fairly valued to slightly overvalued. The forward P/E of 16.9x is below the trailing P/E of 22.8x, suggesting earnings growth is expected, but the PEG ratio of 0.26 indicates the stock may be undervalued relative to its growth rate. However, the price-to-book ratio of 20.3 is elevated, and the stock trades above the analyst average target of $395.25. Compared to the drug manufacturing industry, Amgen's valuation is in line with peers, but its high leverage warrants a discount. The market appears to be pricing in moderate growth and successful execution on the pipeline, leaving little room for disappointment.
From a risk/reward perspective, AMGN is a Hold at current levels. The stock trades at $414.87, above the analyst average target of $395.25, implying limited upside. The forward P/E of 16.9x is attractive, but the high debt-to-equity ratio of 6.31 and regulatory overhangs pose risks. The dividend yield of 2.9% and strong free cash flow of $10.2 billion provide some downside support. For long-term investors, a pullback to the $350–370 range would offer a more favorable entry point. For those already holding, the stock remains a solid core healthcare position with potential catalysts from MariTide.
AMGN is more suitable for long-term investment. The company has a diversified portfolio, a strong dividend (2.9% yield), and a pipeline with long-term growth potential. The beta of 0.41 indicates low volatility, making it less ideal for short-term trading. Earnings visibility is moderate, with quarterly volatility, but the overall trajectory is stable. A minimum holding period of 2-3 years is recommended to allow for pipeline catalysts and deleveraging to materialize. Short-term traders might find opportunities around binary events like MariTide data, but the risk/reward is less favorable for trading given the stock's low beta and institutional ownership.